RE:FDA Moving the Goal Posts ?I suppose the most logical answer is that the company and FDA believe this is a great treatment that can do even better for patients. And if you're going to do a second or third treatment at 360 days or even beyond, then obviously you need to check for efficacy beyond those timelines.
This gives them a chance to find the best protocol for patients for commercialization has the phase 2 trial comes to a conclusion.